Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$24.22M, compared with -$27.11M a year earlier. Trailing-twelve-month operating income was -$122.21M.
Context
- Operating income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 10 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -50.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$24.22M+37.1% QoQ
- Last fiscal yearDec 2025
- -$125.1M-50.6% YoY
- LTMMar 2026
- -$122.21M-31.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +10.7% | +100.0% | +89.3 pp |
| 1 year | -50.6% | +100.0% | +150.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (125.1M) USD
- Year-over-year change
- -50.6%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (125.1M) | -50.6% |
| FY2024 | 2024-12-31 | (83.06M) | -129.6% |
| FY2023 | 2023-12-31 | (36.18M) | -249.0% |
| FY2022 | 2022-12-31 | (10.37M) | — |
Operating Income vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's LTM Mar 2026 operating income of -$122.21M is the 6th highest of the 10 companies compared; the peer median is -$66.85M.
- Its year-over-year change of -31.3% is the 5th highest of 9, against a peer median of -10.6%.
- Operating income amounts to 611.0% of revenue for RAPP, versus a peer median of 17.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $122.33M | -49.2% | — | 10.2% | |
| LTM Mar 2026 | $54.9M | +178.5% | — | — | |
| LTM Mar 2026 | -$42.84M | +20.1% | — | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$46.86M | — | — | — |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | -$66.85M | -256.5% | — | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$122.21M | -31.3% | — | 611.0% |
| LTM Jun 2026 | -$188.54M | +17.6% | — | 24.3% | |
| LTM Mar 2026 | -$210.04M | -140.9% | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$223.08M | +18.7% | — | — |
| LTM Sep 2026 | -$406.72M | -38.8% | — | — | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | -$66.85M | -10.6% | — | 17.2% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 15K | 112K | 839K | 1.02M |
| Gross Profit | (15K) | (112K) | (839K) | (1.02M) |
| Gross Margin | — | — | — | — |
| Research & Development | 9.12M | 28M | 60.94M | 94.79M |
| Selling, General & Admin | 1.37M | 8.07M | 22.12M | 30.31M |
| Operating Expenses | 10.35M | 36.07M | 82.22M | 125.1M |
| Depreciation & Amortization | 15K | 112K | 839K | 1.02M |
| EBITDA | (10.35M) | (34.66M) | (77.47M) | (124.08M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (10.37M) | (36.18M) | (83.06M) | (125.1M) |
| Operating Margin | — | — | — | — |
| Interest Income | 0 | 2.53M | 12.14M | 13.62M |
| Interest Expense | 285K | 0 | 0 | 0 |
| Other Income / Expenses | (285K) | 1.4M | 4.75M | 13.62M |
| Income Before Tax | (10.65M) | (34.78M) | (78.31M) | (111.48M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 10K | 0 | 0 |
| Net Income | (10.65M) | (34.79M) | (78.31M) | (111.48M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.29) | (0.95) | (3.78) | (2.86) |
| EPS (Diluted) | (0.29) | (0.95) | (3.78) | (2.86) |
| Weighted Avg Shares | 20.12M | 18.08M | 20.74M | 46.98M |
| Weighted Avg Shares (Diluted) | 20.12M | 18.08M | 20.74M | 46.98M |
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.